Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

Evercore ISI sees cheap buying opportunities in various stock market sectors as the trade war sends stocks into a bear market ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy recommendation. Analyst Price Forecast Suggests 61.57% Upside As of March ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.